European health insurance does not cover experimental stem-cell therapies for hypertension. Private out-of-pocket cost is standard, ranging €3,500–7,000 per infusion. Clinical-trial participation may offer free or subsidised access. Some cardiovascular research foundations or patient advocacy groups provide financial assistance for trial-enrolled patients. United Kingdom NHS cover is restricted to registered research protocols; private UK centres charge £3,000–6,000 per infusion. Patients should explore trial eligibility before pursuing private treatment, as hypertension is a chronic disease requiring long-term management.
Arterial hypertension stem-cell treatment costs typically range €3,500–6,500 per infusion, depending on cell source and formulation. Exosome-based therapies, when offered, may cost similarly to MSCs or slightly higher due to manufacturing complexity. Single-infusion protocols are more common in hypertension than multi-cycle regimens, potentially reducing total expense compared to other conditions. Placental MSCs are favoured for cost-efficiency and cardiovascular safety profile. Home-based blood-pressure monitoring adds minimal cost but is essential for outcome assessment. European hospital-affiliated programmes typically charge €3,500–5,000; private cardiovascular clinics may exceed €6,500. Insurance rarely covers experimental therapy, necessitating out-of-pocket payment.
Sunt un candidat? → · Arterial Hypertension: full overview → · Cost Hipertensiune Arterială → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită